Metagenomi Therapeutics, Inc. (MGX) vs Sangamo Therapeutics, Inc. (SGMOQ)

Metagenomi Therapeutics, Inc. and Sangamo Therapeutics, Inc. are both Biotechnology companies. Metagenomi Therapeutics, Inc. and Sangamo Therapeutics, Inc. are of similar size ($43.4M and $41.9M). Sangamo Therapeutics, Inc. grew revenue faster over the last twelve months: −45.8% against −59.8%. Sangamo Therapeutics, Inc. has the higher net margin (−356.9% vs −689.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Sangamo Therapeutics, Inc. leads on 9 and Metagenomi Therapeutics, Inc. on 4.

Valuation

Metric MGX SGMOQ Biotechnology median
P/E n/m n/m 7.88
P/S 3.19 1.58 11.47
P/B 0.38 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.49 n/m 0.74
EV/Sales (3.47) 1.79 10.73
Earnings yield (216.52%) (271.43%) (28.84%)
Free cash flow yield (198.11%) (165.83%) (23.03%)

Profitability

Metric MGX SGMOQ Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (741.58%) (357.55%) 0.00%
Net margin (689.20%) (356.89%) 0.00%
Free cash flow margin (632.67%) (261.76%) 0.00%
Return on equity (60.61%) 1,755.72% (57.72%)
Return on assets (41.91%) (168.79%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MGX SGMOQ Biotechnology median
Revenue growth (TTM) (59.84%) (45.80%) 5.64%
EPS growth (last fiscal year) 0.00% 10.20% —
Revenue growth, 5-year CAGR — (19.66%) 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MGX SGMOQ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.50 0.70 4.73
Net debt to EBITDA 1.71 0.18 0.96

Dividend

Metric MGX SGMOQ Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric MGX SGMOQ Biotechnology median
Market cap 43.44m 41.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack